2023年4月13日

TORL BioTherapeutics,洛杉磯的生物製藥公司致力於開發新的癌症治療、生物製劑係列B關閉了158美元融資。圓是由高盛資產管理,在加州大學的參與下,辦公室的首席投資官,百時美施貴寶公司,深入追蹤資本,頂點企業HC,摩爾戰略投資,考恩醫療投資、感知Xontogeny風險基金,和現有的投資者包括亞曆山大風險投資和繳納的合作夥伴。生命科學投資負責人阿米特Sinha在高盛資產管理,和琳恩希利·,醫學博士,President and CEO of Lyell Immunopharma, will join TORL Board of Managers as part of Series B financing. The company intends to use the funds to to advance TORL-1-23, a first-in-class, clinical-stage ADC targeting Claudin 6, TORL-2-307, a clinical-stage ADC targeting Claudin 18.2 and other novel clinical and preclinical stage programs. Co-founded by acclaimed oncologist Dennis Slamon, M.D., Ph.D., of University of California at Los Angeles (UCLA) and entrepreneur and CEO David Licata, as well as leadership from a distinguished set of industry veterans, including Executive Chairman Mark Alles, former Chairman and CEO of Celgene Corporation, TORL BioTherapeutics is a clinical-stage biopharmaceutical company with the objective of developing novel, antibody-based therapeutics to transform the lives of cancer patients. Its lead candidate, TORL-1-23, is a CLDN6-directed ADC developed for patients across multiple cancer types. The company also has two other clinical-stage programs; an ADC and mAb targeting CLDN 18.2. Additionally, TORL is developing a broad pipeline of novel preclinical ADCs and mAb in oncologic indications with a high unmet medical need. TORL is headquartered in Los Angeles. FinSMEs 13/04/2023